Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background & Aims</h3><p>We investigated the incidence and factors associated with relapse of hepatitis B virus (HBV) infection in patients with levels of HB surface antigen (HBsAg) below 100 IU/mL after cessation of entecavir or tenofovir disoproxil fumarate (TDF) treatment.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We collected data from patients with chronic HBV infection without cirrhosis treated with entecavir from 2007 and 2015 or TDF from 2011 through 2016 in Taiwan. We identified 135 patients with levels of HBsAg below 100 IU/mL at the end of treatment (79 entecavir and 56 TDF) and collected data from them for a median 87 weeks (interquartile range, 48–161 weeks) for use as the development set. We collected data from 108 patients from separate medical centers in Taiwan, followed for a median 126 weeks (interquartile range, 61–214) weeks, and used these as the validation group. Post-treatment virologic relapse was defined as a serum level of HBV DNA above 2000 IU/mL and clinical relapse was defined as level of alanine aminotransferase (ALT) greater than 40 U/L and level of HBV DNA above 2000 IU/mL.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>In the development group, the 5-year incidences of virologic relapse, clinical relapse, and HBsAg loss were 40.9%, 32.5%, and 47%, respectively. Baseline level of HBV DNA and end of treatment level of HBsAg were independently associated with relapse. In the development group, 17.3% of patients with end of treatment levels of HBsAg below 40 IU/mL had a virologic relapse within 5 y whereas 67.6% of patients with a level of HBsAg of 40 IU/mL or more had a virologic relapse within 5 y (<em>P</em><.001); proportions of patients with clinical relapses were 10.2% (HBsAg below 40 IU/mL) and 57.6% (HBsAg ≥40 IU/mL; <em>P</em><.001). In the validation groups, for patients with end of treatment HBsAg levels below 40 IU/mL or ≥40 IU/mL, the rates of virologic relapse 5 y were 31.1% and 80.5% (<em>P</em><.001); rates of clinical relapse were 14.2% and 50.3% (<em>P</em><.001), respectively. Rates of virologic and clinical relapse within 5 y were low (below 10%) in patients with a combination of end of treatment level of HBsAg below 40 IU/mL and baseline HBV DNA level below 5×10<sup>4</sup> IU/mL, or baseline hepatitis B core-related antigen level below 4 log U/mL in the development group.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>An end of treatment level of HBsAg of 40 IU/mL or lower is optimal for stopping nucleos(t)ide analog therapy. Waiting to stop therapy until patients have a combination of baseline levels of HBV DNA of 5×10<sup>4</sup> IU/mL or HBcrAg of 4 log U/mL and end of treatment level of HBsAg of 40 IU/mL might reduce the risk of HBV relapse.</p>

Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B

Higher HBeAg-reversion virological relapse and lower sustained remission after treatment cessation in tenofovir-treated HBeAg-positive patients

Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment

Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.

A comparison of the therapeutic efficacy of Tenofovir Disoproxil Fumarate and Entecavir in patients with chronic Hepatitis-B

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study

Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort

Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials

Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels

Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

Comparing Long-Term Outcomes of Entecavir and Tenofovir Disoproxil Fumarate in Liver Transplant Patients

Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate Versus Emtricitabine and Tenofovir Disoproxil Fumarate As Treatments for Patients with Chronic Hepatitis B

Entecavir vs. tenofovir disoproxil fumarate in the treatment of chronic hepatitis B patients with severe acute exacerbation

Letter: Distinct Hepatitis B Virus Relapse Rates After Discontinuing Tenofovir And Entecavir Therapy In Chronic Hepatitis B Patients

Risk factors for relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?

Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.

Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL

Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients